Erratum to: Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice (Lipids, (2017), 52, 5, (415-422), 10.1007/s11745-017-4246-1);Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice

Lipids

Volumn 52, Issue 5, 2017, Pages 415-422

  Choi, Sun Young ^a   Park, Jong Sung ^b   Roh, Mee Sook ^b   Kim, Chong Rak ^c   Kim, Moo Hyun ^b   Serebruany, Victor ^d  

^a Daegu Health College   (South Korea)

^b Dong A University   (South Korea)

^c Inje University   (South Korea)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adiponectin; Atorvastatin; Fibrosis; Protein kinase; Rat model

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; ATORVASTATIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ADIPOQ PROTEIN, MOUSE; ANGIOTENSIN II; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART TISSUE; HEART WEIGHT; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION REGULATION; GENE KNOCKOUT; GENETICS; HEART DISEASE; METABOLISM; PHOSPHORYLATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANGIOTENSIN II; ANIMALS; ATORVASTATIN CALCIUM; COLLAGEN TYPE I; COLLAGEN TYPE III; FIBROSIS; GENE EXPRESSION REGULATION; GENE KNOCKOUT TECHNIQUES; HEART DISEASES; INJECTIONS, SUBCUTANEOUS; MALE; MICE; PHOSPHORYLATION; TREATMENT OUTCOME;

EID: 85018753499     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-017-4296-4     Document Type: Erratum

References (27)

1. Beauloye C, Bertrand L, Horman S, Hue L (2011) AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res 90(2):224–233
2. Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8(10):774–785
3. Zhang P, Hu X, Xu X, Fassett J, Zhu G, Viollet B, Xu W, Wiczer B, Bernlohr DA, Bache RJ, Chen Y (2008) AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 52(5):918–924
4. Du J, Guan T, Zhang H, Xia Y, Liu F, Zhang Y (2008) Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblasts. Biochem Biophys Res Commun 368(2):402–407
5. Stuck BJ, Lenski M, Böhm M, Laufs U (2008) Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem 283(47):32562–32569
6. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8(11):1288–1295
7. Xu A, Vanhoutte PM (2012) Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol 302(6):H1231–H1240
8. Fujita K, Maeda N, Sonoda M, Ohashi K, Hibuse T, Nishizawa H, Nishida M, Hiuge A, Kurata A, Kihara S, Shimomura I, Funahashi T (2008) Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler Thromb Vasc Biol 28(5):863–870
9. Konishi M, Haraguchi G, Ohigashi H, Ishihara T, Saito K, Nakano Y, Isobe M (2011) Adiponectin protects against doxorubicin-induced cardiomyopathyby anti-apoptotic effects through AMPK up-regulation. Cardiovasc Res 89(2):309–319
10. Zhou Q, Liao JK (2010) Pleiotropic effects of statins-Basic research and clinical perspectives. Circ J 74(5):818–826
11. Yamamoto C, Fukuda N, Jumabay M, Saito K, Matsumoto T, Ueno T, Soma M, Matsumoto K, Shimosawa T (2011) Protective effects of statin on cardiac fibrosis and apoptosis in adrenomedullin-knockout mice treated with Ang II and high salt loading. Hypertens Res 34(3):348–353
12. An Z, Yang G, He YQ, Dong N, Ge LL, Li SM, Zhang WQ (2013) Atorvastatin reduces myocardial fibrosis in a rat model with post-myocardial infarction heart failure by increasing the matrix metalloproteinase-2/tissue matrix metalloproteinase inhibitor-2 ratio. Chin Med J (Engl) 126(11):2149–2156
13. Rodrigues Díez R, Rodrigues-Díez RR, Lavoz C, Rayego-Mateos S, Civantos E, Rodríguez-Vita J, Mezzano S, Ortiz A, Egido J, Ruiz-Ortega M (2010) Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. PLoS One 5(11):e14145
14. Rupérez M, Rodrigues-Díez R, Blanco-Colio LM, Sánchez-López E, Rodríguez-Vita J, Esteban V, Carvajal G, Plaza JJ, Egido J, Ruiz-Ortega M (2007) HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 50(2):377–383
15. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, Shyy JY (2006) Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 114(24):2655–2662
16. Hermida N, Markl A, Hamelet J, Van Assche T, Vanderper A, Herijgers P, van Bilsen M, Hilfiker-Kleiner D, Noppe G, Beauloye C, Horman S, Balligand JL (2013) HMG CoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome. Cardiovasc Res 99(1):44–54
17. Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, Zhang M (2009) Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 26(4):958–964
18. Blanco-Colio L, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Egido J (2008) Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol 586(1–3):259–265
19. Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H, Kojima S, Funahashi T, Sakamoto T, Horibata Y, Watanabe K, Koga H, Sugamura K, Otsuka F, Shimomura I, Ogawa H (2007) Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 194(2):e43–e51
20. Inami N, Nomura S, Shouzu A, Omoto S, Kimura Y, Takahashi N, Tanaka A, Nanba M, Shouda Y, Iwasaka T (2007) Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb 36(1):1–8
21. Essick EE, Ouchi N, Wilson RM, Ohashi K, Ghobrial J, Shibata R, Pimentel DR, Sam F (2011) Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling. Am J Physiol Heart Circ Physiol 301(3):H984–H993
22. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY (2010) Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122(7):717–728
23. Zadelaar S, Kleemann R, Verschuren L, de der Vries-Van Weij J, van der Hoom J, Princen HM, Kooistra T (2007) Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27(8):1706–1721
24. Nie P, Li D, Hu L, Jin S, Yu Y, Cai Z, Shao Q, Shen J, Yi J, Xiao H, Shen L, He B (2014) Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors. PLoS One 9(5):e97009
25. Hunyady L, Catt KJ (2006) Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 20(5):953–970
26. Serebruany VL, Miller M, Pokov AN, Malinin AI, Lowry DR, Tanguay JF, Hennekens CH (2006) Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol 97(9):1332–1336
27. Han SH, Quon MJ, Kim JA, Koh KK (2007) Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 49(5):531–538